Obermatt
See Similar Stocks →

Vaxcyte

NSQ:PCVX · US92243G1085
BiotechnologySmall

360

54
Medium confidence — indicative
Profit price35
Cash yield1
Price/Sales16
Price/Book39
Return on Capital38
Cash Return on Capital33
Return on Equity48
Profit margins—

Cash truth not applicable for financial companies.

Sales growth—
Profit Growth1
Long-Term EPS Growth51
Reinvestment41
Price momentum42
Debt load61
Refinancing43
Debt Payback1
Liquidity57
Analyst ratings39
Opinion Changes50
Price Target Upside98
Market mood93
Value Creation0/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Vaxcyte doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Based on 4/5 components.

Profile

CountryUSA
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQGS
Founded2013
Employees488
Websitevaxcyte.com
ISINUS92243G1085
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)D.J. US Health Care
Themes
ImmunologyInfectious DiseasesVaccinesBiopharmaBiotechnologyHealth Care

Description

Vaxcyte, Inc., a clinical-stage vaccine innovation company, engineers high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. The company is re-engineering the way highly complex vaccines are made through the XpressC…

Analysis

Middle-of-the-road

Vaxcyte, Inc. sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is moderate; the safety picture is adequate. The company scores 0/20 on our value-creation score: not creating value.

Flags to be aware of: Some accounting patterns deserve a closer look. As always: this describes the company's numbers; it is not a recommendation.

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
16
—
—
—
Price/Earnings
69
—
—
—
Price/Book
39
—
—
—
Dividend Yield
—
—
—
—
Value (overall)
53
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Vaxcyte with its peers
Tonix Pharmaceuticals
NAQ:TNXP
37
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Immuneering
NMQ:IMRX
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Vir Biotechnology
NSQ:VIR
56
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
Benitec Biopharma
NAQ:BNTC
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Tevogen Bio Holdings
NMQ:TVGN
—
CountryUSA
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
Disc Medicine
NMQ:IRON
5
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →